BSE
INDOCO

INDOCO REMEDIES LTD.

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

INDOCO REMEDIES LTD. Stock Price

Vitals

Today's Low:
₹323
Today's High:
₹343.5
Open Price:
₹328.1
52W Low:
₹307
52W High:
₹423.1
Prev. Close:
₹324.15
Volume:
158201

Company Statistics

Market Cap.:
₹29.47 billion
Book Value:
111.55
Revenue TTM:
₹16.69 billion
Operating Margin TTM:
12.91%
Gross Profit TTM:
₹11.47 billion
Profit Margin:
8.53%
Return on Assets TTM:
8.57%
Return on Equity TTM:
14.72%

Company Profile

INDOCO REMEDIES LTD. had its IPO on under the ticker symbol INDOCO.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. INDOCO REMEDIES LTD. has a staff strength of 6,000 employees.

Stock update

Shares of INDOCO REMEDIES LTD. opened at ₹328.1 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹323 - ₹343.5, and closed at ₹339.85.

This is a +4.84% increase from the previous day's closing price.

A total volume of 158,201 shares were traded at the close of the day’s session.

In the last one week, shares of INDOCO REMEDIES LTD. have increased by +8.98%.

INDOCO REMEDIES LTD.'s Key Ratios

INDOCO REMEDIES LTD. has a market cap of ₹29.47 billion, indicating a price to book ratio of 3.7843 and a price to sales ratio of 2.3701.

In the last 12-months INDOCO REMEDIES LTD.’s revenue was ₹16.69 billion with a gross profit of ₹11.47 billion and an EBITDA of ₹2.86 billion. The EBITDA ratio measures INDOCO REMEDIES LTD.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, INDOCO REMEDIES LTD.’s operating margin was 12.91% while its return on assets stood at 8.57% with a return of equity of 14.72%.

In Q1, INDOCO REMEDIES LTD.’s quarterly earnings growth was a negative -36.2% while revenue growth was a positive 4.7%.

INDOCO REMEDIES LTD.’s PE and PEG Ratio

Forward PE
15.2207
Trailing PE
20.7425
PEG

Its diluted EPS in the last 12-months stands at ₹15.42 per share while it has a forward price to earnings multiple of 15.2207 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into INDOCO REMEDIES LTD.’s profitability.

INDOCO REMEDIES LTD. stock is trading at a EV to sales ratio of 2.5082 and a EV to EBITDA ratio of 12.3066. Its price to sales ratio in the trailing 12-months stood at 2.3701.

INDOCO REMEDIES LTD. stock pays annual dividends of ₹2.25 per share, indicating a yield of 0.46% and a payout ratio of 14.58%.

Balance sheet and cash flow metrics

Total Assets
₹16.58 billion
Total Liabilities
₹4.25 billion
Operating Cash Flow
₹0
Capital Expenditure
₹0
Dividend Payout Ratio
14.58%

INDOCO REMEDIES LTD. ended 2024 with ₹16.58 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹16.58 billion while shareholder equity stood at ₹10.28 billion.

INDOCO REMEDIES LTD. ended 2024 with ₹0 in deferred long-term liabilities, ₹4.25 billion in other current liabilities, 184300000.00 in common stock, ₹10.10 billion in retained earnings and ₹900000.00 in goodwill. Its cash balance stood at ₹109.30 million and cash and short-term investments were ₹173.40 million. The company’s total short-term debt was ₹0 while long-term debt stood at ₹1.44 billion.

INDOCO REMEDIES LTD.’s total current assets stands at ₹8.08 billion while long-term investments were ₹0 and short-term investments were ₹40.00 million. Its net receivables were ₹3.51 billion compared to accounts payable of ₹1.23 billion and inventory worth ₹3.26 billion.

In 2024, INDOCO REMEDIES LTD.'s operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, INDOCO REMEDIES LTD. paid ₹0.15 in dividends in 2024.

Other key metrics

Current Trading Price
₹339.85
52-Week High
₹423.1
52-Week Low
₹307
Analyst Target Price

INDOCO REMEDIES LTD. stock is currently trading at ₹339.85 per share. It touched a 52-week high of ₹423.1 and a 52-week low of ₹423.1. Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was ₹326.09 and 200-day moving average was ₹346.91 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 6007.1% of the company’s stock are held by insiders while 1845.4% are held by institutions.

Frequently Asked Questions About INDOCO REMEDIES LTD.

The stock symbol (also called stock or share ticker) of INDOCO REMEDIES LTD. is INDOCO

The IPO of INDOCO REMEDIES LTD. took place on

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
ORIENTAL TRIMEX LTD. (ORIENTALTL)
₹7.24
-0.43
-5.61%
Tarc Ltd (TARC)
₹86.84
-5.12
-5.57%
₹5.59
-0.05
-0.89%
₹3.06
-0.11
-3.47%
₹679.3
-34.05
-4.77%
₹35.34
-0.55
-1.53%
₹12.87
-0.32
-2.43%
₹63.36
-0.17
-0.27%
₹211.93
-1.26
-0.59%
Angel One Ltd (ANGELONE)
₹1771.75
-107.4
-5.72%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
₹0.14
0.07
+100%
₹0.12
0.04
+45.29%
₹0.96
0.05
+5.4%
₹1.34
-0.35
-20.71%
Humbl Inc (HMBL)
₹0
0
0%

Top Gainers

Last Price
Chg
Chg%
₹0
0
+172200%
₹0
0
+51200%
₹283
280.03
+9428.62%
₹11.2
10.57
+1667.68%
Latch Inc (LTCHW)
₹0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
₹0.19
-123.15
-99.85%
₹0
-0.11
-99.55%
₹0
-0
-97.96%
₹0
-0.01
-93.94%
₹0.01
-0.06
-92.24%

About

Indoco Remedies Limited manufactures, markets, and sells formulations and active pharmaceutical ingredients in India and internationally. The company’s products portfolio includes respiratory products, such as Karvol Plus, Febrex Plus, Dropizin, and Tuspel; stomatologicals products that include Sensodent-K, Sensoform Toothpaste, Sensoform Gum Paint, Rexidin M, Rexidin SRS, RR Sensoform Dental, Sensodent-KF, Poviclean, Rexidin, Sensodent-R, Snowdent, Kidodent, Rexidin Plus, and Dentogel; gastrointestinal products, such as Carmicide, Cyclopam, Cyclopam Plus, Cyclomeff, and Nosic; pain/analgesics products that include Lignox A and Lignox ; and ophthal/otologicals products, such as Renolen, Homide, Dexoren ” S, Zincoren, Bfloren, Dexoren, Otorex, Mofloren-D, Mofloren ” BF, Macuchek, and Mofloren LP. It also provides vitamins/minerals/nutrients that include Methycal, Cital UTI, SM Fibro, Coloferrin, Cal Aid, and MCBM DHA; urology products, such as Cital-H and Cital; Cloben G, Noxa, and Scabex for dermatology; ATM, Clygan, Vepan, and Oxipod for anti-infectives; Hemsyl for blood related therapies; MCBM 69 and D-Chiro for gynecological; Aloja and Aloja M for Anti-Diabetics; and Spear for anti-haemorrhoidal. In addition, the company provides analytical services, such as impurity profile, particle size analysis, heavy metal analysis, polymorphism and compatibility studies, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Further, it offers architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India.

Address